Zhongyuan Union

Zhongyuan Union is a prominent Chinese biotechnology company primarily focused on the industrialization of stem cell and gene technologies. The company operates a comprehensive business model that includes stem cell banking (umbilical cord blood and mesenchymal stem cells), genetic testing, and the development of regenerative medicine products. As one of the earliest listed biotech firms in China, it has established a nationwide network for cell resource storage and clinical applications. Zhongyuan Union is actively advancing several cell therapy candidates through clinical trials, targeting indications such as graft-versus-host disease and degenerative conditions. The company's operations are supported by high-standard GMP manufacturing facilities and extensive R&D collaborations within the precision medicine sector.